We are live on ! Find out more
CARM

Carisma Therapeutics
CARM

Delisted

CARM was delisted on the 10th of October, 2025.

Back to rankings

1 hedge funds and large institutions have $4 invested in Carisma Therapeutics in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% less funds holding

Funds holding: 3 → 1 (-2)

100% less capital invested

Capital invested by funds: $47.9K → $4 (-$47.9K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
1
Holders Change
-2
Holders Change %
-66.67%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
MC
Merck & Co
New Jersey
-$47.9K
2
GSEP
Golden State Equity Partners
California
-$6

CARM Hedge Fund Activity: Q2 2026 in Review

1 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q2 2026, worth a combined $4 — down 100% from $47.9K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of CARM and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Merck & Co, exiting entirely with an estimated $47.9K sold.

  • 1 institutional investor held Carisma Therapeutics (CARM) as of Q2 2026, down from 3 in Q1 2026.
  • Funds reported $4 of Carisma Therapeutics stock for Q2 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Carisma Therapeutics positions in Q2 2026 and 2 closed out, a net change of -2 holders.
  • The largest Carisma Therapeutics seller in Q2 2026 was Merck & Co, an estimated $47.9K sold.

Based on aggregated 13F filings for Q2 2026.